Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Polydefkis

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 25, 2022
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trialDavid Adams, Ivailo L Tournev, Mark S Taylor, et al.
Pharmacology Research & Perspectives|July 5, 2024
A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areataSamira Anderson, Guido Cavaletti, Linda J Hood, et al.
European Journal of Pharmacology|October 1, 2018
Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent modelsAlessia Chiorazzi, Krystyna M Wozniak, Rana Rais, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 1, 2018
Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trialMarcia Waddington-Cruz, Elizabeth J Ackermann, Michael Polydefkis, et al.
Journal of Neurology|November 16, 2019
Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosisAlejandra González-Duarte, John L Berk, Dianna Quan, et al.
Journal of Neurology|February 8, 2020
Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosisAlejandra González-Duarte, John L Berk, Dianna Quan, et al.
Cancer Research|December 2, 2017
Peripheral Neuropathy Induced by Microtubule-Targeted Chemotherapies: Insights into Acute Injury and Long-term RecoveryKrystyna M Wozniak, James J Vornov, Ying Wu, et al.
Journal of Neurology|December 20, 2019
Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosisTeresa Coelho, Aaron Yarlas, Marcia Waddington-Cruz, et al.
Neurology|October 15, 2020
Idiopathic distal sensory polyneuropathy: ACTTION diagnostic criteriaRoy Freeman, Jennifer S Gewandter, Catharina G Faber, et al.
The Lancet. Neurology|November 19, 2020
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension studyDavid Adams, Michael Polydefkis, Alejandra González-Duarte, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 25, 2022
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trialDavid Adams, Ivailo L Tournev, Mark S Taylor, et al.
Pharmacology Research & Perspectives|July 5, 2024
A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areataSamira Anderson, Guido Cavaletti, Linda J Hood, et al.
European Journal of Pharmacology|October 1, 2018
Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent modelsAlessia Chiorazzi, Krystyna M Wozniak, Rana Rais, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 1, 2018
Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trialMarcia Waddington-Cruz, Elizabeth J Ackermann, Michael Polydefkis, et al.
Journal of Neurology|November 16, 2019
Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosisAlejandra González-Duarte, John L Berk, Dianna Quan, et al.
Journal of Neurology|February 8, 2020
Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosisAlejandra González-Duarte, John L Berk, Dianna Quan, et al.
Cancer Research|December 2, 2017
Peripheral Neuropathy Induced by Microtubule-Targeted Chemotherapies: Insights into Acute Injury and Long-term RecoveryKrystyna M Wozniak, James J Vornov, Ying Wu, et al.
Journal of Neurology|December 20, 2019
Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosisTeresa Coelho, Aaron Yarlas, Marcia Waddington-Cruz, et al.
Neurology|October 15, 2020
Idiopathic distal sensory polyneuropathy: ACTTION diagnostic criteriaRoy Freeman, Jennifer S Gewandter, Catharina G Faber, et al.
The Lancet. Neurology|November 19, 2020
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension studyDavid Adams, Michael Polydefkis, Alejandra González-Duarte, et al.
Pageof 9